Nymox Pharma (NYMX) Announces NX-1207 Phase 3 Extension in BPH Met Primary Endpoint
Tweet Send to a Friend
Nymox Pharma (Nasdaq: NYMX) announced that the Company's U.S. long-term extension prospective double-blind Phase 3 BPH studies NX02-0017 and NX02-0018 ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
